查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179897

2023-2030 年全球血管造影設備市場

Global Angiography Devices Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內 (2023-2030)，血管造影設備的全球市場規模預計將以 6.2% 的複合年增長率增長。

血管造影系統是一種醫學成像設備，可以顯示體內血管和器官的內部（管腔），特別關注動脈、靜脈和心室。 包括血管造影系統、導管、導絲、球囊、造影劑、血管閉合裝置、血管造影配件等。

市場動態

心血管疾病病例的增加、老年人口的增加、生活方式的改變、心血管疾病意識的提高以及市場開發預計將推動全球血管造影設備市場的增長。.

新產品的發布將在預測期內推動全球血管造影設備市場。

血管造影新產品的推出將在預測期內推動全球血管造影設備市場。 例如，在 , 2020 年北美放射學會 (RSNA) 虛擬會議上，GE Healthcare 推出了 Allia IGS 7 血管造影系統。 該系統利用人工智能來擴大旋轉血管造影的使用。 同樣在 2021 年 11 月，Philips通過為其 Hybrid AngioCT 套件配備突破性的光譜 CT 成像技術，展示了其對介入醫學的認識。 通過將公司專有的 Spectral CT 7500 系統和圖像引導治療系統 Azurion 和 FlexArm 集成到一個單一的介入套件解決方案中，Philips將為介入醫師提供對這兩種重要成像模式的即時訪問。我希望能夠訪問 .

此外，2022 年 4 月，GE Healthcare 推出了 Discovery IGS 740 移動血管造影系統。 不受束縛的 Discovery IGS 740 提供出色的房間設計和坐姿靈活性。 Discovery 的無軌設計和可調節的寬孔 C 形臂定位為醫生提供了卓越的舒適性和控制力。 此外，大型探測器涵蓋了廣泛的 2D 和 3D 解剖結構。 同樣，2022 年 11 月，Genesis Metec Group 宣布推出 TriReme Medical LLC 設計的巧克力觸感藥物塗層球囊 PTA 導管，用於治療股淺動脈和膕動脈外周動脈疾病患者。FDA（食品和藥物）行政）批准。 因此，上述數據表明，在預測期內，產品推出的增加將推動全球血管造影設備的增長。

嚴格的法規和高成本阻礙了全球血管造影設備市場的增長。

但是，主要市場參與者經常從市場召回產品，這限制了預測期內全球血管造影設備的增長。 例如，2021 年 7 月，美敦力 (Medtronic) 發現了 54,997 件召回的 pc，其中在血管造影期間用於將導管引入血管的導絲組件在運往醫院之前未經過消毒。 此外，2021 年 9 月，Cordis 召回了帶有不透射線標記帶的 SUPER TORQUE MB 血管造影導管，原因是標記帶可能發生遷移或誤插入。 FDA 將其歸類為 I 類，即最嚴重的召回。

COVID-19 影響分析

COVID-19 大流行對全球血管造影市場產生了負面影響。 因為在大流行期間，血管造影手術明顯減少。 例如，英國心血管介入學會對大流行關閉期間在英國進行的所有經皮冠狀動脈介入治療 (PCI) 與大流行前 PCI 進行了回顧性比較，並進行了分析。 結果，PCI 減少了 49%，其中穩定型心絞痛減少了 66%，ST 段抬高 MI (STEMI) 的 PCI 減少了 33%。 此外，大流行病對全球血管造影設備產生了負面影響，因為它改變了人們對健康生活方式的看法並減少了心血管疾病病例數。

內容

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 心血管疾病增加
      • 老年人口增加
      • 市場策略
    • 約束因素
      • 產品市場召回
      • 嚴格監管
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 血管造影系統
  • 導管
  • 導絲
  • 氣球
  • 造影劑
  • 血管閉合裝置
  • 血管造影配件

第 8 章按應用程序類型

  • 診斷
  • 治療

第 9 章按技術類型

  • X光
  • 核磁共振
  • CT

第 10 章技術

  • 冠狀動脈
  • 血管內治療
  • 神經血管

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準

第13章公司簡介

  • Medtronic Plc
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Abbott
  • Boston Scientific Corporation
  • Teleflex Incorporated
  • B.Barun Melsungen
  • Siemens Healthineers
  • Lepu Medical
  • GE Healthcare
  • Haemonetics Corporation
  • Cook Medical Inc.

第14章數據M

簡介目錄
Product Code: DMMD1651

Market Overview

The global angiography devices market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 6.2% during the forecast period (2023-2030).

Angiography devices are medical imaging devices used to visualize the inside, or lumen, of blood vessels and organs of the body, with a particular interest in the arteries, veins, and heart chambers. These include Angiography Systems, Catheters, Guidewires, Balloons, Contrast Media, Vascular Closure Devices, and Angiography Accessories.

Market Dynamics

The rising cases of cardiovascular diseases, growing geriatric populations, lifestyle changes, increasing awareness about cardiovascular diseases, and market developments are expected to fuel the global angiography devices market growth.

The new product launches boost the global angiography devices market during the forecast period.

The new product introduction for angiography boosts the global angiography devices market during the forecast period. For instance, in the Radiological Society of North America (RSNA) virtual meeting in 2020, GE Healthcare revealed its Allia IGS 7 angiography system. The system utilizes artificial intelligence to amplify the use of rotational angiography. Also, in November 2021, Royal Philips disclosed its perception of interventional medicine by including its breakthrough spectral CT imaging technology into a hybrid Angio CT suite. Philips expects to deliver interventionalists instantaneous table-side access to these two key imaging modalities by integrating the company's unique Spectral CT 7500 system and its Image-Guided Therapy System, Azurion, with FlexArm in a single interventional suite solution.

Additionally, in April 2022, GE Healthcare launched its Discovery IGS 740 mobile angiography system. The untethered Discovery IGS 740 delivers excellent room design and sitting flexibility. The Discovery's rail-free design and adjustable wide-bore C-arm positioning deliver exceptional comfort and control to the practitioners. Moreover, its large detector covers extensive anatomies in both 2D and 3D. Likewise, in November 2022, Genesis MedTech Group received the Food and Drug Administration (FDA) approval for its Chocolate Touch Drug-coated Balloon PTA Catheter, designed by TriReme Medical LLC, indicated for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery. Thus, the mentioned data indicates that the increasing product introductions drive the growth of global angiography devices in the forecasted period.

The stringent regulations and high costs hinder the global angiography devices market growth.

However, the reoccurring product recalls from the market by key market players are restraining the growth of global angiography devices during the forecasted period. For instance, in July 2021, Medtronic's recalled 54,997 guidewire components used during angiography to place catheters into the vascular system because the devices were not sterilized before being shipped to hospitals. Also, in September 2021, Cordis Recalled its SUPER TORQUE MB angiographic catheter with radiopaque marker bands due to the potential for marker bands to move or mislodge. The FDA has recognized this as a Class I recall, the most serious recall.

COVID-19 Impact Analysis

The COVID-19 pandemic had a negative impact on the global Angiography Devices market since, during the pandemic, there was a large downfall in Angiography procedures. For instance, the British Cardiovascular Interventional society performed a retrospective analysis of all percutaneous coronary interventions (PCI) performed in the United Kingdom during the lockdown imposed by the pandemic in comparison with PCI volumes in the pre-pandemic period. The retrospective analysis concluded that there was 49% less PCI, with stable angina being hit the hardest, showing a 66% reduction, while the PCI for ST-elevation MI (STEMI) was down by 33%. Furthermore, the pandemic changed people's perspective toward healthy lifestyle choices, which caused a reduction in the cases of cardiovascular diseases, therefore impacting global angiography devices negatively.

Segment Analysis

Coronary heart disease is predicted to have a high demand during the forecast period (2022-2029).

Coronary heart disease is a heart disease in which the heart's arteries are unable to deliver sufficiently oxygen-rich blood to the heart muscles. It is the top reason for death. The reason for coronary heart disease relies on the type. Coronary artery disease is usually induced by cholesterol, a waxy substance that assembles up inside the lining of the coronary arteries, creating plaque. This buildup can partly or completely block blood flow in the heart's large arteries. The coronary microvascular condition occurs when the heart's tiny blood vessels do not typically work. For most individuals, coronary heart disease is preventable with a heart-healthy lifestyle.

Since the number of coronary heart disease cases is growing, coronary angiography is estimated to dominate the global angiography devices market throughout the forecast period. For instance, the American Heart Association estimated that globally, 244.1 million people were living with ischemic heart disease (IHD) in 2020, and it was more dominant in males than in females (141.0 and 103.1 million people, respectively). The highest prevalence rates of IHD were in North Africa and the Middle East, Central and South Asia, and Eastern Europe, and IHD mortality rates were highest in North Africa, the Middle East, Eastern Europe, and Central Asia in 2020. Thus, the mentioned data indicates that coronary angiography will dominate the global angiography devices market during the forecast period.

Geographical Analysis

North America is predicted to command the global angiography devices market.

North America is estimated to hold a large market over the forecast period (2022-2029) because of the growing cases of cardiovascular conditions and the existence of key market players in this region. For instance, according to the CDC, a U.S. American dies every 34 seconds because of cardiovascular disease. Cardiovascular disease caused over 697,000 deaths in 2020. Moreover, the existence of key market players such as Abbott, Haemonetics Corporation, Boston Scientific Corporation, Teleflex Incorporated, Medtronic, and Cook Medical Inc., having considerable percentages of the global angiography devices market through different market strategies, are based in the United States, secures the dominance of this region over the global angiography devices market. For instance, in May 2022, Teleflex Incorporated, a leading global medical technology provider, was granted Health Canada approval for its MANTA Vascular Closure Device, the first commercially available biomechanical vascular closure device developed particularly for large bore femoral arterial access site closure. This approval marks an essential landmark in the regulatory strategy to extend the availability of the MANTA Device globally and delivers access to another uniquely developed device from Teleflex to Canadian clinicians.

Also, in January 2021, Haemonetics Corporation ("Haemonetics"), a global medical technology company concentrated on delivering inventive medical solutions to drive better patient outcomes, acquired a privately-held Cardiva Medical, Inc. ("Cardiva"), an industry-leading manufacturer of vascular closure systems based in Santa Clara, California. Haemonetics enhances its penetration into the large and growing interventional cardiology and electrophysiology markets with this acquisition. Therefore, the data indicate that North America Holds most of the global market.

Competitive Landscape

The major global angiography devices market players are Abbott, Boston Scientific Corporation, Teleflex Incorporated, Medtronic, B.Barun Melsungen, Siemens Healthineers, Lepu Medical, GE Healthcare, Haemonetics Corporation, and Cook Medical Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Angiography Devices market globally. For instance, in October 2022, Lepu Medical obtained the MDR certificate issued by the BSI Netherlands Notified Body (2797) for its Ultraskin Hydrophilic Guide Wire and approved it for sale in the EU market. The certificate is valid for five years. Ultraskin Hydrophilic Guide Wire is the second product of Lepu Medical's high-risk class III product certified under MDR.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic, Plc. for angiography devices contains Launcher: A coronary guide catheter comes with the performance advantages expected from a market leader, including a wide variety of curve shapes for transradial and femoral percutaneous coronary intervention (PCI).

The global angiography devices market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Prevalence of Cardio-vascular diseases
      • 4.1.1.2. Growing Geriatric Population
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. Product Market Recalls
      • 4.1.2.2. Stringent Regulation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Angiography Systems
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Catheters
  • 7.4. Guidewires
  • 7.5. Balloons
  • 7.6. Contrast Media
  • 7.7. Vascular Closure Devices
  • 7.8. Angiography Accessories

8. By Application Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 8.1.2. Market Attractiveness Index, By Application Type
  • 8.2. Diagnostic
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Therapeutic

9. By Technology Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 9.1.2. Market Attractiveness Index, By Technology Type
  • 9.2. X-Ray
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. MRI
  • 9.4. CT

10. By Procedure

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
    • 10.1.2. Market Attractiveness Index, By Procedure
  • 10.2. Coronary
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Endovascular
  • 10.4. Neurovascular

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Medtronic Plc
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Abbott
  • 13.3. Boston Scientific Corporation
  • 13.4. Teleflex Incorporated
  • 13.5. B.Barun Melsungen
  • 13.6. Siemens Healthineers
  • 13.7. Lepu Medical
  • 13.8. GE Healthcare
  • 13.9. Haemonetics Corporation
  • 13.10. Cook Medical Inc.

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us